Medical - Diagnostics & Research
Build Your Comparison
Side-by-side financial analysisStock Comparison
BLLN vs PGNY vs KO vs NTRA vs ILMN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Beverages - Non-Alcoholic
Medical - Diagnostics & Research
Medical - Diagnostics & Research
BLLN vs PGNY vs KO vs NTRA vs ILMN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Healthcare Information Services | Beverages - Non-Alcoholic | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $4.65B | $2.09B | $355.61B | $30.37B | $24.45B |
| Revenue (TTM) | $355M | $1.29B | $49.28B | $2.50B | $4.39B |
| Net Income (TTM) | $25M | $68M | $13.70B | $-226M | $853M |
| Gross Margin | 70.4% | 24.1% | 61.7% | 65.2% | 67.1% |
| Operating Margin | 10.2% | 7.5% | 29.3% | -13.0% | 20.9% |
| Forward P/E | 102.7x | 20.8x | 25.3x | — | 30.8x |
| Total Debt | $109M | $24M | $45.49B | $214M | $2.55B |
| Cash & Equiv. | $496M | $112M | $10.27B | $1.08B | $1.42B |
BLLN vs PGNY vs KO vs NTRA vs ILMN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Progyny, Inc. (PGNY) | 100 | 103.2 | +3.2% |
| The Coca-Cola Compa… (KO) | 100 | 184.9 | +84.9% |
| Natera, Inc. (NTRA) | 100 | 425.3 | +325.3% |
| Illumina, Inc. (ILMN) | 100 | 44.7 | -55.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BLLN vs PGNY vs KO vs NTRA vs ILMN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BLLN is the clearest fit if your priority is growth exposure.
- Rev growth 100.0%, EPS growth 106.8%
- 100.0% revenue growth vs ILMN's -0.8%
PGNY has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- beta 0.61
- Lower volatility, beta 0.61, Low D/E 4.7%, current ratio 2.73x
- Beta 0.61, current ratio 2.73x
- Lower P/E (20.8x vs 30.8x), PEG 3.11 vs 7.29
KO is the #2 pick in this set and the best alternative if valuation efficiency is your priority.
- PEG 2.26 vs ILMN's 7.29
- 27.8% margin vs NTRA's -9.0%
- 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend
NTRA is the clearest fit if your priority is long-term compounding.
- 17.3% 10Y total return vs KO's 121.1%
ILMN ranks third and is worth considering specifically for momentum and efficiency.
- +82.7% vs BLLN's -7.2%
- 13.4% ROA vs NTRA's -10.4%, ROIC 16.8% vs -36.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 100.0% revenue growth vs ILMN's -0.8% | |
| Value | Lower P/E (20.8x vs 30.8x), PEG 3.11 vs 7.29 | |
| Quality / Margins | 27.8% margin vs NTRA's -9.0% | |
| Stability / Safety | Beta 0.61 vs BLLN's 1.91, lower leverage | |
| Dividends | 2.5% yield; 56-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +82.7% vs BLLN's -7.2% | |
| Efficiency (ROA) | 13.4% ROA vs NTRA's -10.4%, ROIC 16.8% vs -36.1% |
BLLN vs PGNY vs KO vs NTRA vs ILMN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BLLN vs PGNY vs KO vs NTRA vs ILMN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
PGNY leads in 1 of 6 categories
NTRA leads 1 • KO leads 1 • BLLN leads 0 • ILMN leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — BLLN and KO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 139.0x BLLN's $355M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to NTRA's -9.0%. On growth, BLLN holds the edge at +83.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $355M | $1.3B | $49.3B | $2.5B | $4.4B |
| EBITDAEarnings before interest/tax | $44M | $100M | $15.5B | -$313M | $1.1B |
| Net IncomeAfter-tax profit | $25M | $68M | $13.7B | -$226M | $853M |
| Free Cash FlowCash after capex | $28M | $181M | $12.6B | $92M | $989M |
| Gross MarginGross profit ÷ Revenue | +70.4% | +24.1% | +61.7% | +65.2% | +67.1% |
| Operating MarginEBIT ÷ Revenue | +10.2% | +7.5% | +29.3% | -13.0% | +20.9% |
| Net MarginNet income ÷ Revenue | +7.1% | +5.2% | +27.8% | -9.0% | +19.4% |
| FCF MarginFCF ÷ Revenue | +7.9% | +14.0% | +25.5% | +3.7% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +83.8% | +1.4% | +12.1% | +38.8% | +4.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +4.8% | +70.6% | +18.2% | -20.0% | +6.1% |
Valuation Metrics
PGNY leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 27.2x trailing earnings, KO trades at a 98% valuation discount to BLLN's 1587.4x P/E. Adjusting for growth (PEG ratio), KO offers better value at 2.43x vs ILMN's 6.98x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $4.7B | $2.1B | $355.6B | $30.4B | $24.5B |
| Enterprise ValueMkt cap + debt − cash | $4.3B | $2.0B | $390.8B | $29.5B | $25.6B |
| Trailing P/EPrice ÷ TTM EPS | 1587.44x | 40.97x | 27.18x | -139.52x | 29.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 102.72x | 20.82x | 25.27x | — | 30.83x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.12x | 2.43x | — | 6.98x |
| EV / EBITDAEnterprise value multiple | 266.12x | 22.14x | 26.39x | — | 22.56x |
| Price / SalesMarket cap ÷ Revenue | 15.24x | 1.62x | 7.42x | 13.17x | 5.64x |
| Price / BookPrice ÷ Book value/share | 9.65x | 4.62x | 10.40x | 16.93x | 9.22x |
| Price / FCFMarket cap ÷ FCF | 295.98x | 10.88x | 67.15x | 278.35x | 26.26x |
Profitability & Efficiency
Evenly matched — PGNY and ILMN each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-15 for NTRA. PGNY carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs NTRA's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +7.6% | +13.3% | +41.1% | -15.1% | +32.8% |
| ROA (TTM)Return on assets | +5.1% | +9.0% | +13.1% | -10.4% | +13.4% |
| ROICReturn on invested capital | +13.5% | +18.1% | +15.8% | -36.1% | +16.8% |
| ROCEReturn on capital employed | +3.7% | +17.4% | +17.3% | -18.3% | +17.6% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 7 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.23x | 0.05x | 1.33x | 0.13x | 0.94x |
| Net DebtTotal debt minus cash | -$387M | -$88M | $35.2B | -$862M | $1.1B |
| Cash & Equiv.Liquid assets | $496M | $112M | $10.3B | $1.1B | $1.4B |
| Total DebtShort + long-term debt | $109M | $24M | $45.5B | $214M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | 516.43x | — | 10.70x | -34.29x | 12.09x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $20,440 today (with dividends reinvested), compared to $3,663 for ILMN. Over the past 12 months, ILMN leads with a +82.7% total return vs BLLN's -7.2%. The 3-year compound annual growth rate (CAGR) favors NTRA at 62.4% vs PGNY's -12.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +13.2% | +3.5% | +20.3% | -7.3% | +19.8% |
| 1-Year ReturnPast 12 months | -7.2% | +23.6% | +17.2% | +29.0% | +82.7% |
| 3-Year ReturnCumulative with dividends | -7.2% | -32.6% | +47.0% | +328.7% | -20.4% |
| 5-Year ReturnCumulative with dividends | -7.2% | -58.7% | +65.6% | +104.4% | -63.4% |
| 10-Year ReturnCumulative with dividends | -7.2% | +67.1% | +121.1% | +1731.3% | +18.6% |
| CAGR (3Y)Annualised 3-year return | -2.5% | -12.3% | +13.7% | +62.4% | -7.3% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than BLLN's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs BLLN's 72.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 0.61x | -0.20x | 1.24x | 0.99x |
| 52-Week HighHighest price in past year | $138.70 | $28.75 | $84.04 | $256.36 | $177.22 |
| 52-Week LowLowest price in past year | $61.96 | $16.10 | $65.35 | $131.81 | $85.77 |
| % of 52W HighCurrent price vs 52-week peak | +72.9% | +92.6% | +98.3% | +82.7% | +90.8% |
| RSI (14)Momentum oscillator 0–100 | 56.5 | 64.6 | 60.6 | 55.9 | 66.4 |
| Avg Volume (50D)Average daily shares traded | 642K | 1.4M | 12.7M | 1.4M | 1.7M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: BLLN as "Buy", PGNY as "Buy", KO as "Buy", NTRA as "Buy", ILMN as "Buy". Consensus price targets imply 23.6% upside for BLLN (target: $125) vs -5.9% for ILMN (target: $151). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $125.00 | $30.33 | $86.13 | $261.00 | $151.40 |
| # AnalystsCovering analysts | 4 | 20 | 48 | 27 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | +2.5% | — | — |
| Dividend StreakConsecutive years of raises | — | — | 56 | — | — |
| Dividend / ShareAnnual DPS | — | — | $2.04 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +3.9% | +0.2% | 0.0% | +3.0% |
PGNY leads in 1 of 6 categories (Valuation Metrics). NTRA leads in 1 (Total Returns). 2 tied.
BLLN vs PGNY vs KO vs NTRA vs ILMN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BLLN or PGNY or KO or NTRA or ILMN a better buy right now?
For growth investors, BillionToOne, Inc.
(BLLN) is the stronger pick with 100. 0% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate BillionToOne, Inc. (BLLN) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BLLN or PGNY or KO or NTRA or ILMN?
On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 27.
2x versus BillionToOne, Inc. at 1587. 4x. On forward P/E, Progyny, Inc. is actually cheaper at 20. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: The Coca-Cola Company wins at 2. 26x versus Illumina, Inc. 's 7. 29x.
03Which is the better long-term investment — BLLN or PGNY or KO or NTRA or ILMN?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +104. 4%, compared to -63. 4% for Illumina, Inc. (ILMN). Over 10 years, the gap is even starker: NTRA returned +1731% versus BLLN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BLLN or PGNY or KO or NTRA or ILMN?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus BillionToOne, Inc. 's 1. 91β — meaning BLLN is approximately -1053% more volatile than KO relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — BLLN or PGNY or KO or NTRA or ILMN?
By revenue growth (latest reported year), BillionToOne, Inc.
(BLLN) is pulling ahead at 100. 0% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to 0. 7% for Natera, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BLLN or PGNY or KO or NTRA or ILMN?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -9. 0% for Natera, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — BLLN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BLLN or PGNY or KO or NTRA or ILMN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, The Coca-Cola Company (KO) is the more undervalued stock at a PEG of 2. 26x versus Illumina, Inc. 's 7. 29x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Progyny, Inc. (PGNY) trades at 20. 8x forward P/E versus 102. 7x for BillionToOne, Inc. — 81. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLLN: 23. 6% to $125. 00.
08Which pays a better dividend — BLLN or PGNY or KO or NTRA or ILMN?
In this comparison, KO (2.
5% yield) pays a dividend. BLLN, PGNY, NTRA, ILMN do not pay a meaningful dividend and should not be held primarily for income.
09Is BLLN or PGNY or KO or NTRA or ILMN better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). BillionToOne, Inc. (BLLN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, BLLN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BLLN and PGNY and KO and NTRA and ILMN?
These companies operate in different sectors (BLLN (Healthcare) and PGNY (Healthcare) and KO (Consumer Defensive) and NTRA (Healthcare) and ILMN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BLLN is a small-cap high-growth stock; PGNY is a small-cap quality compounder stock; KO is a large-cap quality compounder stock; NTRA is a mid-cap high-growth stock; ILMN is a mid-cap quality compounder stock. KO pays a dividend while BLLN, PGNY, NTRA, ILMN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.